NUVL (Nuvalent) Interest Coverage : No Debt ⁽¹⁾ (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Nuvalent Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Nuvalent's Operating Income for the three months ended in Mar. 2025 was $-94.81 Mil. Nuvalent's Interest Expense for the three months ended in Mar. 2025 was $0.00 Mil. Nuvalent has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Nuvalent Inc has no debt.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Nuvalent's Interest Coverage or its related term are showing as below:

NUVL' s Interest Coverage Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

NUVL's Interest Coverage is ranked better than
98.67% of 377 companies
in the Biotechnology industry
Industry Median: 119.89 vs NUVL: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nuvalent Interest Coverage Historical Data

The historical data trend for Nuvalent's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Nuvalent Interest Coverage Chart

Nuvalent Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Coverage

Get a 7-Day Free Trial

N/A

No Debt

Nuvalent Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Coverage	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Nuvalent's Interest Coverage

For the Biotechnology subindustry, Nuvalent's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuvalent's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvalent's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Nuvalent's Interest Coverage falls into.

Save Embed

;

Save Embed

;

Nuvalent Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nuvalent's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Nuvalent's Interest Expense was $0.00 Mil. Its Operating Income was $-280.37 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Nuvalent had no debt ⁽¹⁾.

Nuvalent's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Here, for the three months ended in Mar. 2025, Nuvalent's Interest Expense was $0.00 Mil. Its Operating Income was $-94.81 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Nuvalent had no debt ⁽¹⁾.

The higher the ratio, the stronger the company's Financial Strength is.

Nuvalent (NAS:NUVL) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Nuvalent Interest Coverage Related Terms

Thank you for viewing the detailed overview of Nuvalent's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvalent Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvalent Inc (NAS:NUVL) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Broadway, 14th Floor, Cambridge, MA, USA, 02142

Website

https://www.nuvalent.com

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Executives

Darlene Noci	officer: See Remarks	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
James Richard Porter	director, officer: President and CEO	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Matthew Shair	director	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Deborah Ann Miller	officer: Chief Legal Officer	C/O NUVALENT, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Alexandra Balcom	officer: Chief Financial Officer	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Christopher Durant Turner	officer: Chief Medical Officer	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
James E Flynn	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Emily Conley	director	C/O NUVALENT, INC., ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA 02142
Anna Protopapas	director	MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Deerfield Mgmt L.p.	director, 10 percent owner, other: * Director by deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p.	director, 10 percent owner, other: Director by Deputization	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Michael L. Meyers	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Deerfield Private Design Fund Iv, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017
Robert Bowers Jackson	director	C/O NUVALENT, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142